Genomics company Pacific Biosciences of California (NASDAQ:PACB) in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below ...

PacBio is down 5.8% since the beginning of the year, and at $1.70 per share, it is trading 36% below its 52-week high of $2.65 from November 2024.

PacBio said it expects new Vega shipments to offset year-over-year declines in Revio instrument sales—while currently installed Revios continue to bring in about $236,000 apiece in annual ...

Pacific Biosciences' Q4'24 results missed estimates. Growth in genetic data usage noted, but research funding uncertainties pose risks. See more on PACB stock here.

Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer Jul. 23, 2025 11:05 AM ET Pacific Biosciences of California, Inc. (PACB) Stock PACB Nelson Alves 3.61K Follower s ...

Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh tariffs and reduced funding for federal health agency National Institutes of Health (NIH), it ...

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million Provided by GlobeNewswire Apr 9, 2025, 6:05:00 AM ...

PacBio has faced tariff headwinds as well. In early April, the company said it would reduce both head count and spending due to supply chain pressures and cutbacks in U.S. government grant ...